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Introduction
Chronic lymphocytic leukaemia (CLL) is a monoclonal 
proliferation of  mature-looking B lymphoid cells with 
attendant peripheral lymphocytosis. This malignancy accounts 
for 17 – 20% of  all haematological malignancies in Nigeria. 
It is the second most common haematological malignancy 
after diffuse large B-cell lymphoma, with 2 – 6 per 100,000 
new cases diagnosed annually4. The prevalence of  CLL has 
been found to be 18.2% of  all lymphoid malignancies.5 
In other studies done in some countries with low socio-
economic status there has been an observed paucity of  
diagnostic capacity and lack of  novel treatment options. The 
incidence varies widely across geographical locations, with 
Asia having a 5-10 fold lower prevalence. 6 This indicates 
the possible role of  genetic factors offering a protective 
role in Asians, as migrated Asians in western countries also 
have a reduced incidence of  CLL. 7 The higher prevalence in 
the resource limited countries, not withstanding their lower 
diagnostic capacity is more in support of  a possible genetic 
aetiopathogenesis. 
The malignancy is commoner in males, mostly seen in the 
elderly (age > 65 years) with some familial tendency being 
alleged.d,8 Clinical presentation varies widely with some 
patients being diagnosed incidentally during a routine full 
blood count check. Staging of  the tumor is usually done at 
diagnosis, using the system described by Rai et al or Binet et 
al, 9 both of  which are used for prognosis and decision on the 
commencement of  therapy. Bone marrow trephine biopsy is 
also done to obtain a higher cell yield for cytogenetic studies 
and recently is being proposed for monitoring of  minimal 
residual disease.10,11 Immuno-phenotyping is important to 
ascertain the monoclonality of  the malignant cells as well 
as differentiate the T from the B cell malignancies.  The 
malignant cells in CLL show co-expression of  CD5, a T cell 
marker and CD 19 12,13 and levels of  monoclonal B cell above 
5 x 109/L is considered diagnostic10,14.
The malignant cells in CLL have been found to have 
undergone somatic hypermutation (antigenic stimulation 
in the germinal centers) and include both the memory and 
marginal zone B cells. 15 CLL cells over-express Bcl-2, an 
anti-apoptotic protein which is thought to immortalize the 
malignant clone. There appears to be a dependence of  CLL 
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Abstract
Background
Chronic lymphocytic leukaemia is a relatively common haematological malignancy affecting older adults, accounting for about 20% of  
haematological malignancies in Nigeria. Diagnosis of  this disease depends on the demonstration of  clonal lymphocytosis > 5 x 109/L 
with a characteristic immunophenotypic pattern amidst other clinical and laboratory features.
Objectives
To determine the predominant clinical and laboratory features of  CLL at presentation and their relationship with patient survival. This 
study also aims at examining the relationship between treatment protocol and outcome.
Methods: This is a retrospective study with 8 years data (2010-2018)collected from four different centers. Data was analyzed using 
SPSS 20.0.
Results
There were a total of  97 cases, with a male: female ratio of  1.1:1. The median age at presentation was 59 years. Approximately 55% 
of  the patients presented at Binet stage C, with splenomegaly in 93.2% and 78% were anaemic. The mean white cell count was 137.9 
± 14.7 x 109/L, with a median absolute lymphocyte count of  86 x 109/L. The commonest treatment regimen was chlorambucil and 
prednisolone and males had a superior response. The number of  chemotherapy cycles, serum alkaline phosphatase and aspartate 
transaminase correlated positively with duration of  survival. Mortality rate over the five year period was 14.3%.
Conclusion
CLL was found to present in younger patients when compared to previous studies with a median age of  57 years at diagnosis. Our 
study showed a slight female preponderance and better response to therapy in males. Majority of  the patients presented in Binet 
stage C and were treated with chlorambucil-based drug combinations compared to more current treatment with Fludarabine-based 
combinations. A high serum alanine transaminase and alkaline phosphatase was found to positively correlate with survival amongst 
this patient population
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cells on the bone marrow microenvironment because CLL 
cells in suspension culture undergo spontaneous apoptosis 
in vitro, except when co-cultured with bone marrow stromal 
cells16. These cells also express (immunoglobulin heavy chain 
variable region genes) IGHV as well as restricted subsets of  
B cell receptors to a larger extent than the normal mature 
B cells. These findings suggest that antigenic stimulation 
plays an important role in the pathogenesis of  CLL.   DNA 
sequencing studies have also detected mutated genes; 
MYD88, NOTCH1, SF3B1 and XPO1, all of  which are 
thought to be of  prognostic importance17. Other important 
biological markers include, lymphocyte doubling time, 
ZAP7018,19, CD3820, serum β-2 microglobulin21, thymidine 
kinase as well as presence of  other cytogenetic abnormalities. 
There exists a remarkable paucity of  investigative facilities 
to attain this depth of  investigation for most patients in 
resource poor settings.
Management protocol for treatment of  CLL includes 
combination of  immunotherapy and standard chemotherapy 
for patients with symptomatic, advanced or progressive 
disease. While for patients with stable disease the “watch 
and wait” algorithm is usually deployed.  In the past 
chlorambucil with or without steroids was the gold standard 
for management of  CLL9. This was been replaced by more 
efficient combinations involving the use of  bendamustine, 
fludarabine, cladribine, alemtuzumab (recombinant anti-
CD52) and rituximab (anti-CD20 monoclonal antibody)22. 
However, these current first line drugs are quite expensive and 
not easily available in the economically disadvantaged parts 
of  the world where treatment is largely still chlorambucil/ 
cyclophosphamide-based. This study is aimed at describing 
the predominant clinical and laboratory features of  CLL 
and their relationship with patient survival. We also intend 
to examine the relationship between treatment protocol and 
outcomes / survival achieved in this milieu of  sub-optimal 
care.
Patients and Methods
Clinical data was obtained from the case notes of  97 patients 
diagnosed with CLL at the University of  Nigeria Teaching 
Hospital, Ituku-Ozalla, University of  Port Harcourt 
Teaching Hospital, Nnamdi Azikiwe University Teaching 
Hospital, Nnewi and Federal Medical Center Abakaliki, 
all in Nigeria.  Data obtained were age, sex, Binet stage, 
spleen size, hepatic and renal function tests, haematological 
parameters and chemotherapeutic regimen used as well as 
the duration from the date of  diagnosis to when the patient 
was last seen.  This was done for all patients diagnosed 
between June 2010 and July 2018, using the patients’ case 
notes, in the wards and clinics ,as well as the admission 
registers from the four different participating hospitals.This 
was done retrospectively for the patients seen prior to 2015 
and prospectively for the patients seen up till July 2018. A 
pre-designed excel data sheet was used for uniform data 
collection from the participating centers. 
Statistics
Data was analyzed using SPSS20.0 (Illinois, Chicago) and 
expressed in tables and figures. The Kaplan Meier survival 
curve and equation was used to assess survival differences 
between groups. Spearman Rho and Kendaull_taub were 
employed to assess correlation and the value < 0.05 were 
assumed to be significant. 
Results
Ninety seven patients were diagnosed and treated for CLL 
in the 4 centers within the 8 year interval. Their ages ranged 
from 29 to 89 years with a median age of  59 years and a 
mean age of  60 years. These consisted of  50 (51.5%) males 
and 47 (48.5%) females, giving a male: female ratio of  1.1:1. 
Majority, 53 (54.6%) of  the patients were of  Binet Stage 
C at diagnosis, while 11.3% and 5.2% of  them presented 
with Binet Stage B and A, respectively. Splenomegaly was 
observed in 93.2% of  the patients and the spleen size ranged 
from 0 to 36 cm below the left costal margin, with a median 
value of  14 cm. 
Clinical and Laboratory Aspect
The median value of  the total white cell count at diagnosis 
was found to be 93.5 x 109/L, while the mean value was 
137.9± 17.1 x 109/L. The median absolute lymphocyte 
count was 86 x 109/L, with a mean value of  136.5 ± 22.7 x 
109/L. The mean Hb at diagnosis was 8.5 ± 0.3 g/dL with 
a median of  8.8g/dL. Seventy-eight percent of  the patients 
were anaemic at diagnosis (Hb < 10g/dL), while 31.5% were 
thrombocytopaenic (platelet count < 100 x 109/L). There 
was no  direct relationship between Hb at presentation 
and the duration of  management/ survival, p = 0.053 
(correlation coefficient 0.224). The Binet stage was also 
found to be associated with the Hb at diagnosis (coefficient 
0.359, p=0.001), spleen size (coefficient 0,275, p=0.014), 
leucocyte count at diagnosis (coefficient 0.215, p=0.032), 
absolute lymphocyte count (coefficient 0.303, p=0.007), 
platelet count at diagnosis (coefficient 0.236, p=0.028) and 
alkaline phosphatase (coefficient 0.312, p=0.019). Coombs 
test was positive in only 2 patients out of  62 tested while 
none of  the patients were HIV positive. Majority of  the 
patients (93/97) had CLL while only 4 of  them had CLL/
PL. The haematological parameters  as well as some of  the 
clinical features of  the patients on presentation is shown on 
Table 1. 
Table 1.Clinical and laboratory parameters at 
presentation and their correlation with survival in CLL 
patients
Parameter N Mean Median Coefficient 
(p value)
Age (years) 97 60 59 0.065 (0.547)
H a e m o g l o b i n 
concentration (g/
dL)
80 8.5 8.8 0.224(0.053)
Leucocyte count ( x 
109/L)
84 137.9 93.5 - 0 . 0 7 9 
(0.463)
Spleen size (cm) 59 16 14 _ - 0 . 0 3 1 
(0.813)
A b s o l u t e 
Lymphocyte count 
( x 109/L)




73 146 132 0.105 (0.391)
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Figure 2 (a-d) shows the Kaplan-Meier survival curve for males 
versus females as well as individuals who received varying 
chemotherapeutic combinations.
Figure 1a shows a bar chart of the spleen size and Hb in males versus 
females. Figure1b shows the distribution of absolute lymphocyte 
count and serum alkaline phophatase amongst the patients in the 
different Binet stages. This liver enzyme also showed a significant 
relationship with both the duration of management/ survival and 




Majority of  the patients (43.1%) were on chlorambucil 
and prednisolone (Chl+P), 27.6% on cyclophosphamide/ 
vincristine/ prednisolone (CVP) and 8.6% 
cyclophosphamide/ prednisolone (C+P) while 2.1% were 
placed on cyclophosphamide/ hydroxodaunorubicin/ 
vincristine/ prednisolone (CHOP). The drug regimen 
used was switched in 27.2% of  the patients and the reason 
was mainly due to poor response to chemotherapy (non-
response, relapse and resistance). The median duration of  
management was 4 months and ranged from 0 to 72 months, 
this was found to show a significant positive correlation with 
the number of  cycles of  chemotherapy, alanine transaminase 
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Fig 2d
The most common co-morbidity in these patients was 
diabetes mellitus which was observed in 28% (5/18) of  the 
patients. This is followed by peptic ulcer disease in 17% 
(3/18). Complications observed in patients on treatment 
included; skin eruptions (pemphigus and shingles inclusive) 
– 12% (3/25), anaemia -20% (5/25), respiratory tract 
infections (including 2 cases of  Tuberculosis) – 16% (4/25). 
However in the majority (70%) of  the patients where these 
were recorded no complication of  the treatment or primary 
disease was noted. The duration of  management/ survival 
was influenced by neither the total white cell count nor the 
absolute values. (p=0.463 and p=0.228, respectively). Males 
showed superior survival rates between the 10th and 48th 
month post-diagnosis compared to females. At the time of  
this report 8 (5 females and 3 males) of  the patients had 
been reported dead representing mortality rate of  14.3% and 
76.4% 5-year survival. 
Discussion
Malignancies are driven by genetic mutations, which confer 
some variability in clinical presentation as well as response 
to treatment. Patients in this study presented at a mean 
age of  59 years and this is similar to what was observed by 
Salawu et al in Ile-Ife23 , while older age groups have been 
predominantly affected in the Europe and United States24 . 
This however implies that a younger age group is affected by 
CLL in Nigeria, thus the need for further investigation into 
the predominant mutations causing this leukaemia in these 
patients. This may also be explained by the recent finding 
of  monoclonal B lymphocytosis with increasing age25, 
considered against the wide gap in life expectancy across the 
2 patient populations. The male: female ratio in our study 
shows a slight male preponderance although previous studies 
have shown either a slight male or female predominance. 
Even though we may not be technologically advanced in 
terms of  diagnostics making for possible misdiagnosis, this 
may imply that there may not be any actual difference in 
prevalence across the sexes. Majority of  patients presented 
in Binet stage C, this is understandable, as in most cases 
lymphocytosis is discovered as an incidental finding from a 
blood count done for other reasons. However the staging 
system is dependent on the haemoglobin concentration; 
a decreasing level of  which this study shows to negatively 
affect survival. In other Nigerian studies higher lymphocyte 
count was found to favor survival23; however this was refuted 
by our study, where no association was observed. It is known 
that the degree of  splenomegaly, lymphadenopathy as well as 
lymphocyte counts are indirect measures of  tumor bulk and 
are expected to hamper longevity. However, our study did 
not reveal this and this may be due the presence or absence 
of  other prognostic markers like ZAP70 and CD38 which 
are not routinely assessed in CLL patients in low and middle 
income countries (LMICs). The serum alkaline phophatase 
at diagnosis showed a positive correlation with the duration 
of  survival. The clinical significance of  this finding is 
currently unknown but requires further investigation as it 
may provide a future laboratory prognostic marker which 
can be easily assessed in resource limited settings. Disease 
presentation at a younger age was found to be associated with 
progressive disease and by extension, reduced survival. This 
may be due to the occurrence of  a different mutation in the 
younger CLL patients which may connote more aggressive 
disease phenotype 6,26. CLL in the elderly might actually be 
“genotypically” different from CLL in the younger adults26,27. 
Chlorambucil-based regimen was used for majority of  the 
patients in this study. Recently re-classification of  CLL 
patients has become necessary with the advent of  the disease 
entity – clinical monoclonal B- lymphocytosis, depending 
on the B cell count28. Majority of  the centers in LMICs 
do not further differentiate their CLL patients based on 
this criterion and might possibly lump both patient groups 
together. None of  the patients were placed on fludarabine 
or rituximab, both of  which, though considered standard 
of  care22, are quite expensive and cannot be afforded by 
most patients in LMICs. The median duration of  follow-
up was 4 months and this portrays the lack of  adequate 
documentation and patient tracking systems. Of  the various 
chemotherapeutic combinations used in the patients in this 
study, patients on chlorambucil/prednisolone were shown 
to have longer duration of  survival. This indicates that this 
combination is still the best of  what is available although 
patients are more likely to benefit from using the more 
standard combinations. Patients treated with fludarabine/ 
cyclophosphamide/rituximab, (FCR) combination has 
been known to achieve deeper remission to the extent of  
eliminating minimal residual disease10,11. This treatment 
target is usually unachievable with the treatment regimen in 
use in LMICs. Better therapeutic options have to be explored 
for the CLL patients in resource-limited settings in order to 
optimize their life expectancy. Unlike other studies29,30,  males 
were shown to have superior survival rates compared to 
females. The reason for this variation is not known and will 
require further research. 
Limitations of the study
This being a retrospective study was hampered by poor 
documentation, and missing data/incomplete data. This has 
affected the depth of  the study. 
Conclusion
CLL was found to affect the younger patients in this 
study with a median age at presentation being of  59 years. 
There was significant association between the serum 
alkaline phophatase levels at diagnosis and the duration of  
management/survival in the CLL patients studied. Majority 
of  the patients received chlorambucil and prednisolone, 
while none received fludarabine-based treatment, with a 
median duration of  4 months follow-up. This portrays sub-
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optimal treatment response with an underlining poor patient 
documentation and tracking system.
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